Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name *
Last Name *
Email Address (Verify) *
We will request your mailing address on the next page.
We will request your mailing address on the next page.

NEW INDICATIONS

Brukinsa Approved for Marginal-Zone Lymphoma and for Waldenström’s Macroglobulinemia

JHOP - October 2021 Vol 11, No 5 - FDA Updates
Download PDF

On September 14, 2021, the FDA accelerated the approval of zanubrutinib (Brukinsa; BeiGene) for adults with relapsed or refractory marginal-zone lymphoma (MZL) who have received ≥1 anti-CD20–based regimens. Two weeks earlier, on August 31, 2021, the FDA accelerated the approval of zanubrutinib for adults with Waldenström’s macroglobulinemia (WM). Zanubrutinib received an orphan designation for these indications.

Zanubrutinib was previously approved for mantle-cell lymphoma.

The approval of zanubrutinib for MZL was based on 2 open-label, multicenter, single-arm clinical trials that together included 86 patients with previously treated MZL. Zanubrutinib was administered orally at 160 mg twice daily or 320 mg once daily.

The efficacy measures were overall response rate (ORR) and duration of response (DOR). The ORR was 56% (95% confidence interval [CI], 43%-68%) in the first study, including 20% complete responses, and 80% (95% CI, 56%-94%) in the second study, including 20% complete responses. The median DOR was not estimable.

Continued approval for this indication may be contingent on confirmatory data from a clinical trial.

The approval of zanubrutinib for WM was based on a noncomparative assessment of response and DOR from the zanubrutinib arms in 2 cohorts of the ASPEN study of patients with WM. Cohort 1 included 201 patients with WM and MYD88 L265P mutation, and cohort 2 included 26 patients with WM and wild-type MYD88 L265P. The major efficacy outcome was ORR. The secondary efficacy measure was DOR.

The ORR to zanubrutinib in cohort 1 was 77.5%, with a 12-month event-free DOR of 94.4%. In cohort 2, among the 26 enrolled patients, the ORR to zanubrutinib was 50%, which included complete and partial responses.

The most common (≥20%) adverse events reported with zanubrutinib are decreased neutrophils, upper-respiratory tract infection, decreased platelet count, rash, hemorrhage, musculoskeletal pain, decreased hemoglobin, bruising, diarrhea, pneumonia, and cough.

Related Items
Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Updates
Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Updates
Welireg FDA Approved for 3 Tumor Types Associated with von Hippel-Lindau Disease
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Updates
Rezurock Novel Oral Therapy FDA Approved for Chronic Graft-Versus-Host Disease
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Updates
Jakafi a New Treatment Option for Chronic Graft-Versus-Host Disease
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Updates
Cabometyx Receives FDA Approval for Differentiated Thyroid Cancer
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Updates
Nivolumab First Immunotherapy Approved for Adjuvant Treatment of Urothelial Carcinoma
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Updates
Jemperli Another Therapy Approved for Patients with dMMR Recurrent or Advanced Solid Tumors
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Updates
Lenvima plus Keytruda a New Combination Approved for Advanced Renal-Cell Carcinoma
JHOP - October 2021 Vol 11, No 5 published on October 14, 2021 in FDA Updates
Pylarify Second Radioactive Imaging Drug FDA Approved for PSMA-Positive Prostate Cancer
Web Exclusives published on October 5, 2021 in FDA Updates
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.